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Abstract
Targeting multiple regulators of tumor angiogenesis have the potential to
improve treatment efficacy. Bevacizumab is a monoclonal antibody directed
against vascular endothelial growth factor and ABT-510 is a synthetic analog of
thrombospondin, an endogenous angiogenesis inhibitor. Dual inhibition may
result in additional benefit. We evaluated the safety, tolerability, and efficacy of
the combination of bevacizumab plus ABT-510 in patients with refractory solid
tumors. We also explored the effects of these agents on plasma-based bio-
markers and wound angiogenesis. Thirty-four evaluable subjects were enrolled
and received study drug. Therapy was well tolerated; minimal treatment-related
grade 3/4 toxicity was observed. One patient treated at dose level 1 had a
partial response and five other patients treated at the recommended phase II
dose had prolonged stable disease for more than 1 year. Biomarker evaluation
revealed increased levels of D-dimer, von Willebrand factor, placental growth
factor, and stromal-derived factor 1 in response to treatment with the combina-
tion of bevacizumab and ABT-510. Data suggest that continued evaluation of
combination antiangiogenesis therapies may be clinically useful.
Introduction
Angiogenesis, the process of new blood vessel formation,
plays a critical role in the growth of tumors. The process
by which tumors develop this angiogenic phenotype has
been termed the “angiogenic switch” [1]. Numerous anti-
angiogenesis strategies have been developed, including the
targeting of proangiogenesis factors such as vascular
endothelial growth factor (VEGF) or its receptors.
Naturally occurring proteins and peptides that possess an-
tiangiogenic properties, including thrombospondin (TSP)
and its analogs, are also being studied as cancer therapies.
The impact of combining agents with complementary
antiangiogenesis mechanisms of action has not been well
studied in patients.
Bevacizumab is a recombinant, humanized, monoclonal
antibody directed against VEGF [2]. VEGF is known
to play a pivotal role in tumor angiogenesis and is a
significant mitogenic stimulus for arterial, venous, and
lymphatic endothelial cells (ECs). VEGF can induce
vascular permeability essential for extracellular remodeling
and can serve as an EC survival factor. Bevacizumab is
approved for use in the treatment of several tumor types
[3].
TSP-1 was the first recognized endogenous inhibitor of
angiogenesis [4] and has been shown to inhibit neo-
vascularization and tumorigenesis in numerous pre-
clinical models [5]. The mechanisms underlying the
antiangiogenic effects of TSP are not well understood but
altered signaling via various integrins, CD36, and CD47
have been implicated as well as sequestration of pro-
angiogenic factors such as VEGF and basic fibroblast
growth factor [6, 7]. Most of the antiangiogenic activity
of TSP has been localized to short amino acid sequences
known as TSP repeats [7]. ABT-510 is a synthetic analog
of an N-terminal region of TSP-1, with amino acid sub-
stitutions that provide greater stability and enhance the
antiangiogenic properties of native TSP-1 [8]. In vitro,
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ABT-510 inhibits chemotactic VEGF–stimulated migra-
tion of human microvascular ECs, EC proliferation, and
tube formation. ABT-510 also induces EC apoptosis at
nanomolar concentrations [5].
ABT-510 has been studied both as a single agent and
in combination with cytotoxic chemotherapies, including
5-fluorouracil/leucovorin and gemcitabine/cisplatin [9–11].
However, ABT-510 has not been studied in combination
with other targeted agents. We sought to evaluate the
impact of combining ABT-510 plus bevacizumab, thereby
targeting both sides of the “angiogenic switch” to achieve
more complete inhibition of angiogenesis and, potentially,
greater control of tumor growth. The objectives of this
phase I study were to evaluate dose limiting and non-dose
limiting toxicities of this combination and to determine
the recommended phase II dose (RPTD) for the combina-
tion of ABT-510 plus bevacizumab in patients with
advanced solid tumors. The study consisted of two
phases, a dose escalation phase meant to identify a RPTD
and a biomarker expanded cohort at the RPTD, which was
meant to better describe the effect of this regimen on several
markers of angiogenesis. During the biomarker expanded
cohort, patients received either monotherapy ABT-510 or
monotherapy bevacizumab followed by the combination of
both agents. The pharmacodynamic effects of drug treat-
ment(s) were evaluated via two methods: multiplex
enzyme-linked immunosorbent assay (ELISA) measure-




Patients with histologically or cytologically confirmed
solid tumor malignancies refractory to standard therapy
or for whom there is no standard therapy were eligible
for enrollment. Additional inclusion criteria included: age
18 years; Karnofsky performance status 70%; normal
organ and marrow function defined by the following:
absolute neutrophil count (ANC) 1500/mm3, platelets
 100 000/mm3, hemoglobin 9.0 g/dL; aspartate ami-
notransferase (AST), alanine aminotransferase (ALT),
2.5 9 upper normal limit (ULN) or 5 9 ULN if
known hepatic metastasis; bilirubin 1.5 9 UNL; urine
protein: creatinine ratio (UPCR) 1.0, creatinine clear-
ance estimated 50 mL/min/1.73 m2; prothrombin time,
international normalized ratio and partial thromboplastin
time (PT/INR/PTT) 1.2 9 ULN.
Patients were excluded if they received prior chemother-
apy, radiation therapy, hormonal, biological therapy, or
investigational agents within 28 days prior to day 1 of study
drug or if they had major surgery within 28 days or minor
surgical procedures within 14 days prior to day 1 of study
drug. Additional exclusion criteria included: known brain
metastases; poorly controlled or clinically significant athero-
sclerotic vascular disease, intraabdominal fistula or abscess,
gastrointestinal perforation, or bleeding event (either gastro-
intestinal or pulmonary) >1 tablespoon within 6 months of
day 1 of study drug; squamous cell carcinoma of the lung;
history of intolerance of prior treatment with ABT-510 or
bevacizumab; history of thrombosis within 3 months of day 1
of study drug or current therapeutic anticoagulation; poorly
controlled hypertension (>160/100); significant previous
treatment-related toxicities that were unresolved; and serious
or poorly controlled medical conditions which could be
exacerbated or that would seriously complicate compliance
with the protocol. Women of child-bearing potential were
required to practice contraception and could not be pregnant
or lactating at any time during the study. This study was
approved by the Duke Institutional Review Board, followed
the guidelines of the Helsinki agreement, and was registered
with ClinicalTrials.gov (NCT00888043). All patients provided
informed written consent for study participation.
Drug administration
Bevacizumab (Avastin, Genentech/Hoffman La-Roche,
Basel, Switzerland) was administered as a bi-weekly intra-
venous (IV) infusion on days 1 and 15 of each 28-day
cycle. The initial infusion was delivered over 90 minutes
with subsequent infusions given over 60 minutes and
then 30 minutes if well tolerated. ABT-510 (Abbott Labo-
ratories, Chicago, IL) was administered by twice daily
subcutaneous (SC) injections; patients were trained to
administer the SC injections at home.
Each new cycle could begin only if the subject met ini-
tial inclusion requirements for hematologic, hepatic, and
renal assessments. There were no dose modifications for
either drug; both drugs were to be held for toxicity occur-
rence unless the toxicity could be attributed primarily to
only one agent (e.g., hypertension for bevacizumab).
Modifications were to be made based on the most severe
toxicity.
Dose escalation
The dose escalation scheme is outlined in Table 1. Dose-
limiting toxicities (DLTs) were evaluated during cycle one
and were defined as follows: hematological toxicity
 grade 4 neutropenia or thrombocytopenia; grade 3
hypertension that was not adequately controlled with the
addition of up to 2 antihypertension medications and
grade 4 hypertension; nausea/vomiting or diarrhea
 grade 3 lasting >4 days despite adequate supportive
care; grade 4 proteinuria or persistent grade 3 proteinuria
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>2.0 after discontinuation of bevacizumab; other clinically
significant nonhematological toxicity  grade 3; any
treatment-related death or hospitalization.
Dose escalation used the standard “3 + 3” design up to
full dose of both agents. The maximal tolerable dose
(MTD) was defined as the dose with 0–1 DLTs. The rec-
ommended phase II dose (RPTD) would be the MTD or,
absent significant toxicities, full doses of both agents.
Once the MTD/RPTD was determined, 20 additional
patients were recruited at this dose level to better define
the safety and clinical activity of the regimen, as well as to
collect biomarker data. These subjects received single agent
therapy at the RPTD, with either ABT-510 or bevacizumab
monotherapy followed by combination therapy. This
design allowed for the comparison of changes in bio-
markers related to each drug individually and in combination.
Patient evaluations
Baseline screening was performed within 2 weeks of the
initiation of protocol therapy. Safety evaluations were
performed weekly during cycle 1 and at the beginning of
each cycle and as clinically indicated for all subsequent
cycles. Assessments included physical examinations with
vital signs and performance status as well as complete
blood count with differential, liver function test and
chemistry panel. UPCR, electrocardiogram (ECG), and
coagulation studies were performed on the first day of
each cycle. Radiographic examination and relevant blood
tumor markers were assessed every other cycle. General
symptom management and supportive care were provided
as clinically indicated to provide optimal patient care.
Adverse events were graded using the National Cancer
Institute common toxicity criteria, version 3.0 [12].
Tumor response was assessed by Response Evaluation Cri-
teria in Solid Tumors (RECIST) criteria every 8 weeks [13].
Patients could continue to receive ABT-510 and bevacizumab
until disease progression, unacceptable adverse event(s), con-
sent withdrawal, or lack of available drug supply.
Biomarkers
Blood was collected from each patient by venipuncture
into a sodium citrate vacutainer (BD Vacutainer, catalog
# 369714; Beckton Dickinson, Franklin Lakes, NJ) at base-
line, at the end of cycle 1 and every 2 cycles thereafter.
After mixing, the tubes were centrifuged at 2500 9 g for
15 minutes. The upper layer of plasma was transferred to
a fresh tube and centrifuged one more time at 2500 9 g
for 15 minutes. This double-spun, platelet-poor plasma
was aliquoted, snap frozen, and stored at 80°C until
use. Plasma samples were analyzed using Searchlight plat-
form (Aushon Biosystems, Inc., Billerica, MA) following
manufacturer’s protocol for the protein analytes listed in
Table 2. Briefly, samples were thawed on ice, centrifuged
at 20 000 9 g for 5 minutes to remove any residual precipi-
tate and appropriately diluted before placement onto Search-
Light plates in duplicate. Samples and standards were
incubated at room temperature for 1 hour while shaking.
Plates were washed three times using a plate washer (Biotek
Instruments, Inc., Model ELx405, Winooski, VT), biotinylat-
ed secondary antibody added, and incubated for an addi-
tional 30 minutes. After three more washes, streptavidin-
HRP was added to the plates, incubated for 30 minutes,
washed again, and substrate added. Images of the plates were
taken within 10 minutes, followed by image analysis using
SearchLight array analysis software.
Wound angiogenesis assay
Skin biopsies were obtained using previously reported
methods [14]. Briefly, before drug treatment, a 4-mm
skin biopsy was performed to stimulate granulation
(wound) tissue formation, and 7 days later, a 5-mm
biopsy was performed in the same location to collect the
resulting granulation tissue. Before each biopsy, the
patient’s skin was locally anesthetized with 1% lidocaine
with epinephrine at a ratio of 1:100,000, mixed with
sodium bicarbonate (8.4%). Topical antibiotic ointment
followed by a nonocclusive bandage was applied to each
wound; patients were given written and verbal wound
care instruction guidelines.
Stimulus and granulation tissue biopsies in the bio-
marker expanded cohort were performed according to the
schedule as follows: day 7 (baseline stimulus), day 1
(baseline granulation), day 8 (monotherapy stimulus),
day 15 (monotherapy granulation), day 22 (combination
therapy stimulus), and day 29 (combination therapy
Table 1. Dose escalation scheme and cycle 1 dose limiting toxicity events (DLTs).
Cohort level ABT-510 (mg, twice daily) Bevacizumab (mg/kg, every 14 days) No. of patients No. of DLTs DLT events
1 50 5 3 0
2 50 10 3 0
3 100 10 6 1 Grade 2 GI bleed
Expanded cohort 100 10 22 0
GI, gastrointestinal.
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granulation). Dermal neovascularization at the wound
periphery was evaluated using a digital camera with a spe-
cial dermatologic adapter (Heine Dermatophote). All the
images were scored using an ordinal 0–4 scoring system
of wound vascularization, with each wound field divided
into 12 clock hours. Each section was scored by two inde-
pendent observers blinded to treatment status or image
timing, and an average vascular score (AVS) was obtained
for each time point [15] Granulation tissue samples
(5-mm biopsies) were homogenized and assessed by
Western blot using antibodies to total-VEGFR2 (Santa
Cruz Biotechnology, Inc, Cat# sc-315, Santa Cruz, CA)
and phospho-VEGFR2 (Cell Signaling Technology,
Cat#2478, Beverly, MA). ELISA assays for TSP-1 and 2
(R&D Systems, Minneapolis, MN) were also performed
on the protein lysates according to manufacturer’s direc-
tions. All assays were done in duplicate.
Statistical analysis
Descriptive statistics were used to summarize demo-
graphic and baseline disease characteristics. Biomarker
assessments were all considered exploratory and therefore
the sample size of 20 patients for the expanded cohort
was based upon practical consideration. For each plasma-
based biomarker, one-sample Wilcoxon signed-rank tests
were performed to investigate whether the log fold change
was different from 0 between end of cycle 1 and baseline.
For the analytes at P < 0.05, average log fold change and
95% confidence intervals were calculated. For AVS, the
median changes and their ranges were tabulated. To
explore any potential correlation between changes in blood
biomarkers and AVSs, Spearman’s correlation coefficients
were computed. SAS version 9.2 and R 2.12 (SAS Institute,
Inc., Cary, NC) were used for the statistical analyses.
Results
General
Between September 2005 and June 2008, 37 patients were
enrolled; a total of 34 patients received bevacizumab at
doses ranging from 5 to 10 mg/kg IV every 14 days and
ABT-510 at doses ranging 50 to 100 mg subcutaneously
twice daily. Of these, 32 were evaluable for response and 33
were evaluable for toxicity. Patient characteristics are listed
in Table 3. Patients were treated in 3 dose levels and in a
biomarker expanded cohort at the MTD/RPTD (Table 1).
Safety/Toxicity
Adverse events for all dose levels are listed in Table 4.
There was one DLT at dose level 3, a treatment-related
hospitalization for gastrointestinal bleed due to a gastric
varix that required endoscopic intervention. Although the
varix was likely pre-existing, a contribution to the bleed-
ing event from study treatment was deemed likely. There
were no DLTs at lower dose levels. The most common
adverse events seen (epistaxis, injection site reaction,
headache, fatigue, and anorexia) were grade 1/2; with
most of these events being grade 1. In addition to the
bleed due to the gastric varix, there was one grade 3
anorexia and one other GI bleed; both of these events
were felt to be treatment related. No significant hemato-
logic toxicity was observed and no patient experienced a
grade 4 or 5 treatment-related adverse events.
Efficacy
In this population of heavily pretreated patients with solid
tumors, there was one RECIST-defined partial response (PR)
Table 2. List of plasma proteins analyzed using SearchLight platform.
Soluble angiogenic factors Matrix-derived angiogenic factors Markers of coagulation
Markers of vascular activation
and inflammation
ANG-2 PEDF MMP2 CRP E-cadherin NT-proBNP
bFGF PlGF MMP9 D-dimer E-selectin MCP-1
HGF VEGF-A Osteopontin PAI-1 active Gro-a P-selectin
IGFBP1 VEGF-C TGFb1 PAI-1 total ICAM-1 SDF-1
IGFBP3 VEGF-D TGFb2 Tissue factor IFNc TNFa
PDGF-AA sVEGFR1 TSP1 vWF IL-6 VCAM-1
PDGF-BB sVEGFR2 TSP2 IL-8
ANG-2, angiopoietin-2; bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; IGFBP, insulin-like growth factor-binding protein;
PDGF, platelet-derived growth factor; PEDF, pigment epithelium-derived factor; PlGF, placental growth factor; VEGF, vascular endothelial growth
factor; sVEGFR, soluble vascular endothelial growth factor receptor; MMP, matrix metallopeptidase; TGFb, transforming growth factor beta; TSP,
thrombospondin; CRP, c-reactive protein; PAI-1, plasminogen activator inhibitor-1; vWF, von willebrand factor; Gro-a, growth regulated onco-
gene-alpha; ICAM-1, intercellular adhesion molecule 1; IFNc, interferon gamma; IL, interleukin; NT-pron-BNP, N-terminal prohormone brain natri-
uretic peptide; MCP-1, macrophage chemoattractant protein-1; SDF-1, stromal cell-derived factor-1; TNFa, tumor necrosis factor-a; VCAM-1,
vascular cell adhesion molecule 1.
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in a patient with thyroid carcinoma treated at the RPTD
who had a 41.2% decrease in disease measurements; this
patient remained on study for 20+ cycles. One patient
treated at dose level 1 and 5 patients treated at the RPTD
had prolonged stable disease for >1 year. This included
one patient each with pancreatic adenocarcinoma
(16 cycles), desmoid tumor (15 cycles), metastatic giant
cell tumor (17+ cycles), endometrial adenocarcinoma
(18+ cycles), cholangiocarcinoma (12 cycles), and neuro-
endocrine tumor of the pancreas (14+ cycles). Of note,
four patients achieving prolonged disease control
(denoted by “+”) stopped treatment due to lack of avail-
ability of ABT-510. Four additional patients had stable
disease for at least 6 months but less than a year.
Biomarker analysis
Plasma-based biomarkers
Levels of several categories of soluble proteins, including
angiogenic factors, coagulation factors, and markers of vas-
cular activation and inflammation, were analyzed at base-
line and at the end of cycle 1. All patients were on
combination therapy at the end of cycle 1. For technical
reasons, samples could not be analyzed at time points
when patients were on ABT-510 and bevacizumab mono-
therapies. Levels of placental growth factor (PlGF) and
stromal-derived factor 1 (SDF-1), two markers previously
described to change with anti-VEGF treatment, were signif-
icantly increased in response to combination treatment in
this study (Fig. 1A and B) [16–18]. D-dimer and von
Willebrand’s Factor (vWF), two coagulation-related mark-
ers not previously described to change in response to either
treatment, were also significantly increased after one treat-
ment cycle (Fig. 1C and D). No consistent changes in
other analytes between baseline and cycle 1 were observed.
Due to the heterogeneous population and small size of this
study, we did not attempt to correlate baseline analyte lev-
els or changes in analyte levels to clinical outcome.
Wound angiogenesis assay
AVS analysis
A novel wound angiogenesis assay was incorporated into
this study to determine if the effects of these antiangio-
genic therapies, bevacizumab and ABT-510, could be
monitored using a dermal wound assay. While not statis-
tically significant, AVS scores were modestly decreased
after combination drug treatment (data not shown).
Spearman-based correlations between changes in AVS
scores and changes in circulating plasma markers were
performed. Changes in transforming growth factor beta1
(TGFb1) and TGFb2 plasma levels were found to mod-
estly correlate to changes in AVS with correlation coeffi-
cients of q = 0.64 and 0.63, respectively. While
unadjusted P-values of TGFb1 and TGFb2 were signifi-
cant at P < 0.01, more stringent multiple parameter test-
ing resulted in false discovery rate (benjamini–hochberg
procedure) of 0.13 for both.











Hypertension 0 0 0 0
Proteinuria 0 0 0 0
Epistaxis 9 0 0 0
Thrombosis 0 0 0 0
Gastrointestinal
Diarrhea 3 2 0 0
Constipation 5 0 0 0
Nausea 4 2 0 0
Vomiting 0 1 0 0
GI bleed 0 0 2 0
Other
Anorexia 4 0 1 0
Fatigue 5 4 0 0
Headache 6 0 0 0
Injection
site reaction
15 0 0 0
Rash 9 0 0 0
Table 3. Patient characteristics.





Age (yrs) Median (range) 56 (19–74)
Karnofsky performance status
Median (range) 90 (70–100)
Number of prior treatments (chemotherapy, radiation)
0 5
1 or 2 9









1Includes one patient each with breast, ovarian, thyroid, melanoma,
hurthle cell, cervical, hepatocellular, desmoid, duodenal, adrenal corti-
coid, sarcoma NOS, giant cell, endometrial, osteosarcoma, clear cell
carcinoma.
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Tissue VEGFR2 and TSP analysis
No consistent changes in the levels of total VEGFR2 or
phospho-VEGFR2 were observed in the granulation tissue
across the cohorts with drug treatment, for either mono-
therapy or for combination treatment. Levels of TSP1 and
TSP2 protein in granulation tissue also did not signifi-
cantly change with either monotherapy or with combina-
tion treatment.
Discussion
This study evaluated the tolerability, antitumor, and anti-
angiogenic activity of the combination of ABT-510 plus
bevacizumab in patients with refractory solid tumor
malignancies. Overall, the combination was very well tol-
erated; most toxicities were grade 1 or 2. There was one
grade 3 gastrointestinal bleed related to a previously
unrecognized gastric varix, which may have been precipi-
tated by study treatment, and one grade 3 anorexia felt to
be related to study treatment. Grade 1/2 irritation at the
ABT-510 injection site and grade 1/2 epistaxis were occa-
sionally seen. No other toxicities traditionally associated
with antiangiogenic agents, including cardiac ischemia,
hypertension, proteinuria, poor wound healing, and/or
bowel perforation, were observed.
With the small number of evaluable patients in this
study (34 treated in total and 28 treated at the RPTD)
and tumor heterogeneity, it is difficult to make any con-
clusions about efficacy of this combination. There was
one PR (thyroid carcinoma). While several antiangiogenic
multikinase inhibitors have shown activity in thyroid can-
cer, most of these agents also inhibit the ret oncogene
[19]. The activity of bevacizumab in thyroid cancer has
not been evaluated. Stable disease lasting at least
6–12 months was noted in four patients (all at the RPTD);
stable disease lasting at least 12 months was noted in six
patients (1 at dose level 1 and 5 at the RPTD). Three of
these patients stopped treatment due to drug supply issues
not due to toxicity or disease progression. Of the patients
with prolonged stable disease, several had tumor types
(neuroendocrine tumor of the pancreas, endometrial
carcinoma, and sarcoma) for which antiangiogenic thera-
pies have reported activity. Interestingly, for patients
with potentially sensitive tumor types, the duration of
stability seen in patients on this trial compares favorably
to the median progression-free survivals reported in the
literature [20–22]. In addition, several patients with
tumor types not known to benefit from anti-VEGF ther-
apy (duodenal adenocarcinoma, squamous cell carcinoma
of the cervix, and cholangiocarcinoma) had stable disease
for at least 6 months. Whether these signs of clinical
activity are related to one or both agents or to patient
selection cannot be determined from the current study.




Figure 1. Waterfall plots of the fold change in PlGF (A), SDF-1 (B), D-dimer (C), and vWF (D) plasma levels on drug treatment in all patients.
Each bar represents the log2 fold change (end of cycle 1/baseline) of the plasma analyte in a single patient, arranged in ascending order.
*Patients that had PR or SD >1 year. The mean log2 ratios and P-value (one-sample Wilcoxon signed-rank test) are included in the inset of each
graph. SDF-1, stromal-derived factor 1; PlGF, placental growth factor; vWF, von Willebrand factor; SD, standard deviation.
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In this study, we measured multiple plasma-based
markers of angiogenesis at baseline and on-treatment;
only effects on combination treatment were evaluable.
Consistent with many published reports evaluating
plasma biomarker responses to various VEGF inhibitors,
including bevacizumab, SDF-1, and PlGF levels were
increased in patients on this study [16–18].
Two coagulation factors, D-dimer and vWF, were
found to be increased. D-dimer and vWF have been asso-
ciated with clinical outcomes in several cancer types [23–
26] and coagulation factors are known to play a key role
in the generation of tumor stroma formation and in the
expression and processing of VEGF and many other
angiogenesis factors, including TSP, PlGF, and SDF-1 [27–
30]. In a small randomized study, increases in D-dimer
were reported to correlate with disease progression in
patients with colorectal cancer treated with bevacizumab
[23]. Bevacizumab has also rarely been associated with
the development of thrombotic microangiopathies, condi-
tions associated with changes in coagulation markers
[31]. The increase in both markers in the current study
were not consistent with these conditions and there was
no clinical or other laboratory evidence (altered platelets,
hemoglobin, PT, PTT, creatinine) for microangiopathies
on this study. The biological and clinical significance of
these changes are not known, particularly as this finding
was noted for patients with both short and prolonged
stable disease and was not associated with thrombosis.
Wound angiogenesis was only slightly affected by
treatment with ABT-510 and bevacizumab as mono-
therapies and/or by combination therapy with both
drugs, as determined by AVSs in a skin punch biopsy
assay. Additionally, no consistent changes were observed
in the activation state of VEGFR2 or in the levels of
TSP1 or TSP2 within the granulation tissue following
either ABT-510 or bevacizumab monotherapy or combi-
nation therapy. Wound healing is orchestrated by the
spatial and temporal expression of proangiogenic and
antiangiogenic factors; it is possible that these molecular
endpoints are dynamic during treatment and our
assessment at only one time point (i.e., 7 days after the
wound stimulus) may have missed an effect window
that might have been seen at another time point. The
correlation of plasma TGFb1 and TGFb2 levels with a
treatment effect on wound vascularization is of uncer-
tain significance in this pilot study. However, it possible
that TGFb levels reflect states of greater or lesser host
wound healing capacity and/or sensitivity to anti-VEGF
or TSP mimetic therapy.
Lastly, combination antiangiogenesis therapy remains
an area of active investigation. Although TSP is among
the first and most promising endogenous antiangiogenesis
inhibitors, developing TSP mimetics has been difficult,
largely due to the large size and multifunctional roles of
TSP and the lack of a well-defined receptor and signaling
pathway. The TSP mimetics ABT-510 and COVX-045 are
no longer in clinical development. Nevertheless, the par-
tial response in one patient and the prolonged stable dis-
ease (6 months) seen in 32% of patients on this study
treated at the RPTD suggest a potential role for combined
anti-VEGF and TSP mimetic therapy. Despite the
reported pharmacokinetic limitations of ABT-510, the
clinical disease control noted above suggests that this
agent may have biological activity in cancer patients.
These data would support continued efforts to under-
stand and potentially develop next generation agents in
this class.
In conclusion, the combination of ABT-510 and bev-
acizumab was well tolerated and clinical activity was
noted in a variety of tumor types. Evaluation of plasma-
based biomarkers revealed up-regulation of D-dimer,
vWF, SDF-1, and PlGF in response to treatment with
ABT-510 plus bevacizumab. These data suggest combina-
tion antiangiogenesis therapies may be clinically useful
and that several biomarker approaches can be used to
describe the effect of these agents.
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